GLP-1 & compounded medication availability in Michigan (2026)

Michigan asks more of a compounding pharmacy than most states do, and since every medication OrderlyMeds ships is a sterile injectable, those extra asks apply to every row of the table below. The state licenses out-of-state pharmacies on the same terms as its own, layers a national-accreditation requirement onto sterile compounding, and its attorney general has been publicly active on counterfeit GLP-1 products. Here is the whole picture, cited.

Conditional state

Availability facts last reviewed: November 16, 2026

All ten lines, measured against Michigan’s rules

Availability of all ten OrderlyMeds product lines in Michigan, with typical delivery times and notes
Product lineAvailable in Michigan?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Filled by Michigan-licensed partner pharmacies meeting the state’s sterile-compounding bar.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days National flat pricing; Michigan’s rules shape the pharmacy, not the price.
NAD+ Yes 8–10 business days Sterile injectable, covered by the accreditation rule cited below.
Sermorelin Yes 8–10 business days Dispensed through the standard OrderlyMeds flow.
Glutathione No N/A Outside the current formulary.
BPC-157 Yes 8–10 business days Injectable peptide; its federal record is set out in its own section.
TB-500 Yes 8–10 business days Injectable peptide. The federal facts below apply in full.
KPV No N/A Not carried anywhere: the peptide formulary is injectable-only.
Epitalon Yes 8–10 business days Injectable peptide; the section below carries its cited record.
MOTS-c Yes 8–10 business days Injectable peptide whose federal entry stands apart from the rest.

Missing-row dishonesty is the one thing this table will never do. A No is printed as a No. Michigan entries reviewed November 16, 2026.

Research peptides in Michigan: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Michigan receives four of these five lines from OrderlyMeds: BPC-157, TB-500, Epitalon and MOTS-c, compounded as sterile injectables and dispensed one patient, one prescription at a time, by pharmacies meeting the state’s accreditation requirement for exactly this kind of preparation. KPV is absent by formulary design: we compound peptides as injectables only. Because these five substances carry five different federal histories, each is stated separately below, for shoppers and skeptics alike.

BPC-157 in Michigan

Dispensed to Michigan patients as a sterile compounded injectable, one prescription per patient. Federal record:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Michigan

Ships to Michigan as a sterile injectable compound on an individual prescription. The cited facts:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Michigan

Not available in Michigan, nor any state, because our peptide compounding is injectable-only and KPV is not.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Michigan

A Michigan-available sterile injectable, individually prescribed. Its federal entry:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Michigan

Reaches Michigan as a sterile compounded injectable, individually prescribed; its federal entry is deliberately not a name-swap of the others:

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

Michigan’s rules for the pharmacies behind this page

Michigan’s framework has three load-bearing pieces for a telehealth patient: full licensure of out-of-state pharmacies, a dedicated accreditation rule for sterile compounding, and a telehealth-prescribing section that asks for follow-up care rather than a prior office visit. A fourth piece, the attorney general’s public posture on counterfeit GLP-1 products, is not a rule at all, but it tells you where the state’s enforcement attention is pointed, and it is worth reading before buying from anyone.

A pharmacy, “whether or not located in this state,” must hold a Michigan license to do business in Michigan, and a pharmacy providing compounding services must be separately authorized for them. MCL 333.17748(1). Source: Michigan Compiled Laws § 333.17748.

A pharmacy providing sterile-compounding services must hold current accreditation from a national accrediting organization approved by the state, or demonstrate USP compliance as the state determines — and every OrderlyMeds line on this page is a sterile preparation, so this rule reaches all of them. MCL 333.17748a. Source: Michigan Compiled Laws § 333.17748a.

Michigan permits a prescriber acting within their scope of practice to issue a prescription on the basis of a telehealth encounter; the section’s conditions concern follow-up care and referral, not a prior in-person examination. MCL 333.16285. Source: Michigan Compiled Laws § 333.16285.

On February 19, 2025, Michigan Attorney General Dana Nessel joined a 38-attorney-general coalition letter urging FDA to intercept counterfeit GLP-1 products, act against sellers of raw GLP-1 active ingredients, and partner with state pharmacy regulators so compounded GLP-1 drugs are produced in a safe, sanitary way. Sources: coalition letter to FDA, Feb. 19, 2025 (hosted by the South Carolina Attorney General) · Michigan AG press release, Feb. 20, 2025.

For a patient in Grand Rapids or Marquette the day-to-day experience is unchanged: eligibility check, evaluation by a Michigan-licensed provider, delivery from a Michigan-licensed pharmacy. The pharmacy behind that package has cleared a higher bar than most states set, which is exactly what you want from the people compounding your injectable.

Michigan availability FAQs

Does compounded semaglutide ship to Michigan?

It does. OrderlyMeds partner pharmacies hold Michigan licenses and meet the state’s sterile-compounding accreditation rule; new customers start at $74/month for the first two months.

What makes Michigan different from neighboring states?

Two things, both cited above: out-of-state pharmacies need a full Michigan license rather than a lighter registration, and sterile compounding carries its own accreditation requirement on top.

Are peptides like BPC-157 and TB-500 available in Michigan?

BPC-157, TB-500, Epitalon and MOTS-c all ship to Michigan as sterile compounded injectables on individual prescriptions. KPV does not, because it sits outside our injectable-only formulary. Each line’s federal record is on this page.

How fast do Michigan orders arrive?

Our published national window is 8–10 business days from signup; Michigan deliveries run on that schedule.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone